Infliximab - Biologic Drug Details

Summary for infliximab

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	6
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for infliximab

Recent Clinical Trials for infliximab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
Asian Institute of Gastroenterology, India	PHASE2
Therakos LLC	PHASE2

See all infliximab clinical trials

Pharmacology for infliximab

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for infliximab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for infliximab Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for infliximab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Infliximab

Last updated: March 12, 2026

What Is Infliximab and Its Market Position?

Infliximab is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). It was developed by Janssen Pharmaceuticals and received FDA approval in 1998 for treating Crohn's disease. It has since gained approval for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Infliximab's revenue in 2022 surpassed $7 billion globally, with primary sales throughout North America, Europe, and select markets in Asia. Its sales are driven by established approvals, high efficacy, and high treatment penetrance.

Market Size and Growth Trends

Historical Revenue and Sales Data

Year	Estimated Global Revenue (USD billion)
2018	6.8
2019	7.1
2020	6.9
2021	7.3
2022	7.2

Revenue growth exhibits a CAGR of approximately 1.3% from 2018 to 2022, reflecting market saturation in mature markets and modest uptake in emerging markets.

Key Growth Drivers

• Expansion of indications, including new autoimmune disorders.
• Increased treatment adherence due to improved formulations and biosimilars.
• Rising prevalence of autoimmune diseases globally.
• Competitive pricing and biosimilar entry influencing market dynamics.

Impact of Biosimilars

Biosimilar versions of infliximab have entered markets since 2013, reducing branded drug prices by approximately 25-50% in Europe and North America. The introduction of biosimilars is expected to reduce infliximab's market share for the originator product over the next five years, with a projected revenue decline rate of 8-10% annually post-2025.

Competitive Landscape

• Key Players: Janssen (Remicade), Celltrion (Remsima), Pfizer/Bioepis (Inflectra), Samsung Bioepis (Flixabi), and Siemens Healthineers (Ytepe).
• Market Share (2022): Janssen maintains approximately 65-70% in North America and Europe. Biosimilars hold 20-25%, with the remainder divided among smaller players.
• Pricing Trends: Originator prices are declining due to biosimilar competition and healthcare payers' cost containment efforts.

R&D and Pipeline Developments

Multiple biosimilars have gained approval across various markets. Janssen is focusing on consolidation of existing indications and exploring combination therapies. Patent expiries in 2023-2024 precipitate greater biosimilar penetration and downward price pressures.

Financial Trajectory

Revenue Forecast (2023-2027)

Year	Estimated Revenue (USD billion)	Growth Rate
2023	6.8	-5% (due to biosimilar entry and price erosion)
2024	6.4	-6%
2025	6.0	-6%
2026	5.5	-8%
2027	5.0	-9%

This trend reflects an accelerating decline due to biosimilar market penetration, profit margin compression, and market saturation.

Cost Dynamics

Research and Development investments focus on refining biosimilar manufacturing processes, developing enhanced formulations, and exploring new indications. Primary expenses relate to clinical trials, manufacturing scale-up, and market access strategies.

Profitability Outlook

Operating margins are projected to decline from approximately 40% in 2022 to 25-30% by 2027, driven by reduced pricing power and increased competitive pressures.

Policy and Regulatory Environment

• Biosimilar approvals are streamlined in the EU and US to facilitate market entry.
• Pricing regulations in Europe, including reference pricing and tendering, further compress margins.
• US patent litigations delayed biosimilar launches until 2023, but recent filings have now stabilized.

Key Takeaways

• Infliximab remains a blockbusting biologic with strong historical sales, but market share is eroding due to biosimilars.
• The global biologic market for autoimmune therapies is expected to grow at a CAGR of 3-4% through 2027, but infliximab's share diminishes.
• Revenue is forecasted to decline 5-9% annually after 2023, aligning with biosimilar penetration.
• Pricing strategies, indication expansion, and biosimilar development are critical to maintaining profitability.

FAQs

1. How does biosimilar competition affect infliximab's revenue?
Biosimilars lower prices, reduce market share, and lead to revenue declines for the originator product, especially after patent expirations.

2. What are the main indications for infliximab?
Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

3. Are there new formulations or delivery methods for infliximab?
Yes. Recent developments include subcutaneous formulations, increasing patient convenience and adherence.

4. What is the potential for infliximab in emerging markets?
Growing autoimmune disease prevalence and biosimilar availability may expand access but are limited by pricing and healthcare infrastructure.

5. Will infliximab remain profitable long-term?
Profitability will decline without adjustment strategies like indication expansion, cost reduction, or pipeline development.

References

1. [1] U.S. Food & Drug Administration. (2022). Infliximab (Remicade) approval information.
2. [2] IQVIA. (2022). Global Market Analytics for Biologics.
3. [3] European Medicines Agency. (2022). Biosimilar infliximab approvals and market data.
4. [4] EvaluatePharma. (2022). 2022 Top-Selling Drugs and Forecasts.
5. [5] IMS Health. (2022). Trends in Biosimilar Adoption across Markets.